End Stage Renal Disease (ESRD) is an irreversible kidney damage that adds a heavy strain on the global healthcare system. Taiwan, which has the highest prevalence of global ESRD, spends an astonishing 7.85% of its total national healthcare budget on the ESRD population, which accounts for a mere 0.3% of its population. Similarly, in US, the number of ESRD patients constitute 1% of the Medicare population, but consumes 7% of the entire Medicare budget. In 2015 alone, the fiscally demanding cure to this disease cost an annual expenditure of US$ 69.45B. For a disease that has a Compound Annual Growth Rate (CAGR) of 6.2%, this is compelling evidence that ESRD urgently requires innovative measures to improve clinical outcomes and lighten financial burdens to global healthcare systems.
As designated step-down institutions where patients visit thrice three times a week, dialysis centres are responsible for specialized renal care provided to the patient. With the global renal manpower shortage, the value proposition for them to adopt NephTech Surveillance Program is compelling:
Improved predictability of stenotic events and upgraded accuracy, in their performance indicators related to elevated quality of care.
Improved efficiency and reputation of the dialysis centre.
International Organization Advocating Surveillance Programme
Judicious and streamlined surveillance workflow for nurses
Improvesd patient outcomes
Reduces losses from missed patient dialysis sessions
Decreases catheter usage
Improves reputation through elevated quality of care
End Stage Renal Disease Patients
Reduces inconvenience of frequent hospitalization
Increases savings due to infrequent hospitalization & associated expenses
Heightenspatient life quality
National Healthcare System
Decreases national hospital utility stress
Decreases national healthcare expenses
Increases savings & lesser expenditure on this financially crippling disease
Elevates profits due to reduction in expenses on ESRD
Better Clinical Outcomes
Author: D. A. Mayer, R. G. Zingale, and M. J. Tsapogas
Journal: Vascular Surgery, vol. 27, no. 9, pp. 647–658, 1993
Author: J. J. Sands, P. A. Jabyac, C. L. Miranda, and B. J. Kapsick
Journal: ASAIO Journal, vol. 45, no. 3, pp. 147–150, 1999
Author: N. Tessitore, G. Mansueto, V. Bedogna et al.
Journal: Journal of the American Society of Nephrology, vol. 14, no. 6, pp. 1623–1627, 2003
Author: H.Hoeben,A.K.Abu-Alfa,R.F.Reilly,J.E.Aruny,K. Bouman, and M. A. Perazella
Journal: American Journal of Nephrology, vol. 23, no. 6, pp. 403–408, 2003
Author: J. Malik, M. Slavikova, J. Svobodova, and V. Tuka
Journal: Kidney International, vol. 67, no. 4, pp. 1554–1558, 2005
Author: L. C. Plantinga, B. G. Jaar, B. Astor et al.
Journal: Nephron—Clinical Practice, vol. 104, no. 4, pp. c151–c159, 2006
Better Vascular Access Longevity
Author: N. Tessitore, G. Lipari, A. Poli et al.
Journal: Nephrology Dialysis Transplantation, vol. 19, no. 9, pp. 2325–2333, 2004
Higher Cost Savings
Author: P. Mccarley, R. L. Wingard, Y. Shyr, W. Pettus, R. M. Hakim, and T. Ikizler
Journal: Kidney International, vol. 60, no. 3, pp. 1164–1172, 2001